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Abstract
Strongyloides stercoralis is a widely distributed parasite that infects 30 to 100 million people
worldwide. In the United States strongyloidiasis is recognized as an important infection in
immigrants and refugees. Public health and commercial reference laboratories need a sim-
ple and reliable method for diagnosis of strongyloidiasis to identify and treat cases and to
prevent transmission. The recognized laboratory test of choice for diagnosis of strongyloidi-
asis is detection of disease specific antibodies, most commonly using a crude parasite ex-
tract for detection of IgG antibodies. Recently, a luciferase tagged recombinant protein of S.
stercoralis, Ss-NIE-1, has been used in a luciferase immunoprecipitation system (LIPS) to
detect IgG and IgG4 specific antibodies. To promote wider adoption of immunoassays for
strongyloidiasis, we used the Ss-NIE-1 recombinant antigen without the luciferase tag and
developed ELISA and fluorescent bead (Luminex) assays to detect S. stercoralis specific
IgG4. We evaluated the assays using well-characterized sera from persons with or without
presumed strongyloidiasis. The sensitivity and specificity of Ss-NIE-1 IgG4 ELISA were
95% and 93%, respectively. For the IgG4 Luminex assay, the sensitivity and specificity
were 93% and 95%, respectively. Specific IgG4 antibody decreased after treatment in a
manner that was similar to the decrease of specific IgG measured in the crude IgG ELISA.
The sensitivities of the Ss-NIE-1 IgG4 ELISA and Luminex assays were comparable to the
crude IgG ELISA but with improved specificities. However, the Ss-NIE-1 based assays are
not dependent on native parasite materials and can be performed using widely available
laboratory equipment. In conclusion, these newly developed Ss-NIE-1 based immunoas-
says can be readily adopted by public health and commercial reference laboratories for rou-
tine screening and clinical diagnosis of S. stercoralis infection in refugees and immigrants in
the United States.
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Author Summary
Strongyloidiasis is a neglected tropical disease that affects millions worldwide and needs
more attention and better diagnostic methods. Strongyloides stercoralis can undergo an au-
toinfection cycle and can cause hyperinfection involving the pulmonary and gastrointesti-
nal systems and disseminated infection in other organs. Although endemic areas are
mostly developing countries in tropical and subtropical regions with only sporadic trans-
mission in temperate areas, the disease is a threat to developed world populations through
immigrants, refugees, travelers, and military personnel. The disease can have catastrophic
effects when a patient is immunocompromised or when an infected organ is transplanted
into a vulnerable recipient. Due to the threat to public health, the intricate life cycle of S.
stercoralis, the need to perform multiple follow-up diagnostics to ensure treatment success,
and the necessity to rule out multiple co-endemic parasitic infections, it is imperative to
develop new diagnostic assays that are simple and efficient while retaining maximal sensi-
tivity and specificity. In this study, we use a well-known recombinant protein, Ss-NIE-1, to
optimize assays using both an ELISA format and a multiplex platform to meet these needs.
Introduction
Strongyloides stercoralis, an intestinal nematode that migrates through the skin and lung, is a
widely distributed disease that infects 30 to 100 million people worldwide [1]. Unlike other hel-
minthic parasites, S. stercoralis can complete its entire life cycle within a single human host
through autoinfection and can cause an asymptomatic chronic infection that may go undetect-
ed for decades in immunocompetent hosts [2, 3]. In the United States, S. stercoralis causes
more deaths than any other soil-transmitted helminth, with mortality rates as high as 87% in
cases of hyper-infection in immunocompromised hosts [3].
The standard diagnosis of strongyloidiasis relies on the detection of larvae in the stool [4],
but a single stool sample analysis will identify no more than 70% of positive cases [5]. Due to
the low sensitivity of the stool assay, immunodiagnosis using a crude antigen-based enzyme-
linked immunosorbent assay (ELISA) has been developed as the laboratory test of choice for
clinical diagnosis of strongyloidiasis. The Immunoglobulin G (IgG) ELISA utilizes crude ex-
tract prepared from L3 S. stercoralis larvae obtained from infected dogs. Reliance on native par-
asite materials and the canine infection model are major disadvantages of this test. As a result,
a number of recombinant antigen-based ELISAs have recently been developed. Recombinant
antigens can be purified easily and can be reproducibly generated in large amounts [6–8]. Anti-
body detection assays utilizing recombinant protein Ss-NIE-1, a 31-kDa antigen derived from
S. stercoralis L3 parasites [8], have reported sensitivities and specificities of 84–98% and 95–
100%, respectively, and are comparable in performance to the crude antigen-based ELISA
[6–13].
We have incorporated Ss- NIE-1 into a standard ELISA format assay and into a fluorescent
bead format assay (Luminex) to detect S. stercoralis-specific Immunoglobulin subtype G4
(IgG4). We have previously used the Luminex system for the simultaneous determination of
IgG antibody responses to multiple infections in a single assay run [14–17] and we hope to add
the new multiplex bead antibody test to our Neglected Tropical Disease assay panel. We com-
pared the performance of the Ss-NIE-1 recombinant antigen-based ELISA and Luminex bead
assays to the published assay performance parameters for the Ss-NIE-1 luciferase immunopre-
cipitation system (LIPS) based assay [6, 10] and the crude antigen-based IgG ELISA [10]. Be-
cause previous research has documented that not all cases of strongyloidiasis are successfully
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treated with a single course of therapy [18], we also used the fluorescent bead assay to deter-
mine if a decrease in antibody was measureable after treatment using a select set of sera.
Materials and Methods
Serum Specimens
Although some samples were exhausted during the initial ELISA development and some new
samples were added during Luminex assay development, the same sets of sera were used for
testing the Ss-NIE-1 ELISA and Ss-NIE-1 Luminex assays and many samples were assayed
using both techniques. The sets of human sera used were: (1) samples proven positive for S.
stercoralis based on the presence of larvae in the stool or sputum (ELISA N = 258, Luminex
N = 175); (2) presumed negative samples from U.S. residents with no history of foreign travel
(ELISA N = 182, Luminex N = 207); (3) a convenience panel of samples from patients with var-
ious diseases other than S. stercoralis focusing mainly on worm infections and including 63
sera from proven cases of lymphatic filariasis from Haiti (ELISA N = 143, Luminex N = 159)
[19]; (4) and sera from patients with S. stercoralis infections, before and after treatment (ELISA
N = 48, Luminex N = 25) [18]. All sera were anonymous and were used in accordance with ap-
proved human subjects’ protocols.
Recombinant Protein Preparation
Ss-NIE-1 ELISA antigen. Ss-NIE-1 with a 6x His tag was expressed in E. coli from a clone
in pET30b (kindly provided by T. Nutman, NIAID, NIH, Bethesda, MD) by Genscript (Piscat-
away, NJ). Expression was analyzed and confirmed by Western Blot using anti- 6xHis antibod-
ies and S. stercoralis positive serum. The protein was purified in a one-step affinity purification
using a Nickel metal affinity column and concentrations were measured with the Bradford pro-
tein assay (Bio-Rad Laboratories, Hercules, CA).
Ss-NIE-1 Luminex antigen. The S. stercoralis Ss-NIE-1 antigen coding sequence (Gen-
Bank AAB97359) was PCR amplified from a clone in plasmid pET29b (kindly provided by F.
Neva, NIAID, NIH, Bethesda, MD) [8] using the following forward and reverse deoxyoligonu-
cleotide primers: 5’-CGC GGA TCC AAT TCG GCA CGA GAT GAA AAT G-3’ and 5’-GCG
GAA TTC TTA TTG TTT ACG TTG TAA AAC GTT TG-3’, respectively. In these sequences,
the restriction sites used for cloning are underlined, and the reverse primer included an in-
frame stop codon shown in italics. Previously reported protocols were used for the PCR ampli-
fication of the target sequence using AmpliTaq gold DNA polymerase (Perkin-Elmer Cetus,
Foster City, CA), for cloning into the BamHI and EcoRI sites of pGEX 4T-2 vector (GE Health-
care, Piscataway, NJ), for expression of the recombinant Schistosoma japonicum glutathione S-
transferase (GST) fusion protein in 2.0 L of E. coli BL21 cells (Stratagene, La Jolla, CA), and for
protein binding to a 10 ml glutathione Sepharose 4B affinity column (GE Healthcare) [20, 21].
Protein was eluted from the column with buffer containing 100 mM Tris at pH 8.0, 500 mM
NaCl, and 30 mM reduced glutathione then immediately diluted with 0.33 volumes of buffer
containing 10 mMNa2HPO4 at pH 7.2 and 0.85% NaCl (PBS) with 8 M urea in order to mini-
mize precipitation. The eluate was centrifuged at 26,000 x g for 10 min at 4°C, and the superna-
tant was immediately loaded onto a 50 ml G-25 Sephadex (GE Healthcare) desalting column
previously equilibrated with buffer containing 25 mM 2-(N-morpholino)-ethanesulfonic acid
(MES) at pH 6.0, 200mMNaCl, and 2 M urea. Protein elution was monitored at 280 nm, and
three 4 ml fractions were pooled for further purification. Dithiothreitol was added to a final
concentration of 1 mM, and the protein was centrifuged as above before loading onto a Mono
S HR 5/5 strong cation exchange column (GE Healthcare). Bound protein was eluted at a flow
rate of 1 ml/ min with buffer containing 25 mMMES at pH 6.0, 2 M urea, and the following
Ss-NIE-1 and Strongyloidiasis
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linear NaCl gradients: 0–400 mMNaCl in 4 min, 400–600 mMNaCl in 10 min, and 600–1000
mM in 4 min. A total of 4.2 mg of protein was collected in three 1-ml fractions at approximate-
ly 0.44 M NaCl in the gradient profile. Purity was estimated to be>98% by SDS polyacryl-
amide gel electrophoresis. The recombinant GST/Ss-NIE-1 fusion protein was used in all
multiplex assays. Protein concentrations were measured with the BCA microassay (Pierce,
Rockford, IL).
Ss-NIE-1 ELISA Development
The development of an IgG4 standard reference curve for the Ss-NIE-1 ELISA was performed
as described by Scheel et al [22]. Immunoglobulin G4, human myeloma plasma was purchased
and stored frozen in 20 mM phosphate, pH 7.4, with 150 mMNaCl and 0.05% Sodium azide
(NaN3) (Athens Research & Technology, Athens, GA). IgG4 was diluted into antigen sensitiz-
ing buffer (ASB) (0.05 M Tris/HCl, pH 8.0 + 1 M KCl + 2 mM EDTA) to create standard curve
points. IgG4 concentrations were chosen based on previous experiments in standard curve de-
velopment and adjusted to produce the highest OD value, ~ 2.0.
Checkerboard titrations for antigen concentration, serum dilution, conjugate dilution, and
substrate 3, 3’, 5, 5’-Tetramethylbenzidine (TMB) time were carried out on Immulon 2HB
Microwell plate (Thermo Scientific, Cat. Number 6506). For optimization of the Ss-NIE-1
ELISA, optimal conditions were chosen based on the signal to noise ratio between defined strong
S. stercoralis positive and normal human serum samples. The optimized Ss-NIE-1 ELISA steps
are as follows: the micro-well plate was sensitized with 100 μL/well of Ss-NIE-1 antigen at a con-
centration of 0.3 μg/mL in antigen sensitizing buffer (0.05 M Tris/HCl, pH 8.0 + 1 M KCl + 2
mM EDTA) for 2 hours at room temperature on a plate shaker. Following antigen sensitization,
the plate was washed 4 times with PBS/0.3% Tween. The plate was blocked for 30 minutes with
100 μL/well of 10 mMNickel Chloride (Aldrich, Cat. Number 339350) in PBS/0.3% Tween/5%
Instant Nonfat Dry Milk (Nestle, Glendale, CA), and then washed as before. StabilCoat Immu-
noassay Stabilizer (SurModics, East Prairie, MN) was then added 100 μL to each well and incu-
bated for 30 minutes on a plate shaker at room temperature. After discarding the blocking
solution, the plate was dried for 4 hours at 30°C in a vacuum oven chamber. The sensitized and
blocked plate was stored at 4°C in sealed aluminum foil with desiccator.
Ss-NIE-1 ELISA Protocol
Human serum samples were tested in 100 μL/well at 1:50 dilution in PBS/0.3% Tween/5% In-
stant Nonfat Dry Milk. Following 30 minutes incubation at room temperature on a plate shak-
er (speed ~ 800 rpm), the plate was washed 4 times with PBS/0.3% Tween. Proper conjugate
concentration of mouse anti-human IgG4 (clone HP6025), affinity purified, horseradish perox-
idase labeled (Southern Biotech, Birmingham, AL; Cat. Number 9200–05) was added to each
well at 100 μL/well at 1:1,000 dilution in PBS/0.3% Tween and incubated 30 minutes at room
temperature on a plate shaker with the plate being washed 4 times following incubation with
PBS/0.3% Tween. The substrate used was SureBlue, 3, 3’, 5, 5’-Tetramethylbenzidine (TMB)
Microwell Peroxidase Substrate (KPL, Gaithersburg, Maryland). We used 100 μL/well of TMB
to develop the plate for 5 minutes, and the reaction was stopped by adding 100 μL 1 N H2SO4
Analyzed ACS Reagent (J.T. Baker, Phillipsburg, NJ). The signal was read at A450nm using a
VersaMax Kinetic ELISA Microplate Reader with SoftMax Pro v5.4 Software (Molecular De-
vices Corporation, Palo Alto, CA).
Ss-NIE-1 and Strongyloidiasis
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Ss-NIE-1 Luminex Assay Development
Protein coupling to MagPlex magnetic beads. Coupling of protein to MagPlex Magnetic
Microspheres (Luminex, Austin, TX) was carried out using EDC-Sulfo NHS protocol [23, 24].
Briefly, beads were washed and activated in buffer containing 50mMMES, pH 5, 0.85% NaCl,
and 0.05% Tween-20. After 40 minutes of incubation using end-over-end mixing in the dark
with Sulfo-NHS and EDC, beads were washed 2 times with MES buffered saline. The activated
beads were then transferred to a new tube and washed once more. Beads were resuspended in
the MES buffer without Tween-20 and 0.3 μg of GST-Ss-NIE-1/1.25 x 10E6 beads were added.
The total volume of reaction was brought to 500 μL with MES buffer without Tween-20. The
coupling was performed for 3 hours in the dark at room temperature by end-over-end mixing.
Beads were blocked with blocking buffer (PBS + 1% BSA + 0.05% sodium azide (NaN3), pH 7.4)
for 30 minutes. The coupled beads were stored at 4°C in PBS + 1% BSA + 0.05% NaN3 + 0.05%
Tween-20 + PMSF (1:500), Pepstatin (1:1000), Leupeptin (1:1000) until used. The concentration
of the beads was determined by viewing them in a hemocytometer using a 20X objective.
Luminex immunoassay. Fifty μL of the working MagPlex microsphere mixture (50 beads/
μL in PBS/0.3% Tween-20/5%—Instant Nonfat Dry Milk) and 50 μL of diluted sera (1:100 in
PBS/0.3% Tween-20/5% Instant Nonfat Dry Milk) were added into each well of Costar 96-well
black, round-bottom plate (Fisher Scientific, Cat.# 3792). After 30 minutes incubation at room
temperature with shaking at speed 6 (~800 rpm), the beads were washed using the Biotek Mag-
netic Washer ELx50 (2 minutes magnetic separation followed by 2 cycles of dispensing 100 μL
of PBS/Tween-20 0.3% and a 40 second soak before aspiration). The complex of antibody and
coupled beads was detected using 50 μL of biotinylated mouse anti-human IgG4 (clone
HP6025, affinity purified, Southern Biotech, Birmingham, AL, Cat. Number 9200–08) diluted
1:200 in PBS-1% BSA, 0.05% NaN3. After 30 minute incubation, the beads were washed as pre-
viously described. As a detector, 50 μL/well of R- phycoerythrin-labeled streptavidin conjugate
(Invitrogen, Cat. # S866) at a 1:250 dilution in PBS-1% BSA, 0.05% NaN3 was added to the well
and incubated for 30 minutes. After washing, the beads were resuspended using 100 μL/well of
PBS-1% BSA, 0.05% NaN3. The mean fluorescence intensity from each well was determined by
using BioPlex manager software, version 6.02 (BioRad) and a Luminex 100 platform.
Data Analysis
Data were tabulated and analyzed using Microsoft Excel. Determination of the cut-off value
and assay performance was calculated using SAS version 9.0. The concentration of Ss-NIE-1
ELISA was measured in in ng/mL; Luminex results are reported as mean fluorescence intensity
minus background blank (MFI). The J-index, a single measurement of assay performance, was
calculated as described previously ([25, 26].
Results
S. stercoralis NIE-1 IgG4 ELISA
The recombinant Ss-NIE-1-His protein expressed at Genscript was successfully used to devel-
op an ELISA (Table 1). Using a cutoff value of 0.80 ng IgG4/mL, the assay correctly identified
245 of 258 parasitologically confirmed strongyloidiasis cases for a sensitivity of 95% (Table 1).
The overall specificity of the ELISA was determined to be 93% using a panel of non-endemic
US controls and sera from patients with other (mainly parasitic worm) diseases (Tables 1 and
2). Among the 142 donors with defined diseases or parasitic infections shown in Table 2, the
specificity was only 86%, but only the two trichuriasis patients were 100% cross-reactive. Al-
though the numbers of samples were also quite small, cross reactivities of 33% were observed
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among sera from echinococcosis, gnathostomiasis, and hookworm patients. Table 2 shows the
cross-reactivity of the various presumed negative sera. Given the likelihood of polyparasitism
among many of these serum donors (i.e., 63 lymphatic filariasis patients from S. stercoralis-en-
demic Haiti), the 99% specificity observed among US negative controls may be a reasonable
upper bound to the value. The J-index, a single measure of assay performance, was 0.88.
Positive sera with low and medium level reactivity were used to measure inter-assay varia-
tion as previously described in the Materials and Methods. The inter-assay coefficient of varia-
tion was determined to be 22% for the low positive control serum and 10% for the medium
positive control serum.
Table 1. Performance of SS-NIE-1 ELISA and Luminex.
Assay Characteristics SS-NIE-1 ELISA 95% CI * Ss-NIE-1 Luminex 95% CI
Cut-off point 0.8 ng IgG4/ mL 8 MFI units
J-index 0.88 0.88
Sensitivity: N Positive/ N Tested (%) 245/258 (95) 92–97 162/175 (93) 88–96
Speciﬁcity: N Negative/ N Tested (%) 303/325 (93) 90–96 349/366 (95) 93–97
Note: * CI = conﬁdence interval
doi:10.1371/journal.pntd.0003694.t001
Table 2. Cross-reactivity of SS-NIE-1 ELISA and Luminex.
SS-NIE-1 ELISA SS-NIE-1 Luminex
Cross reactivity
(%)
No. of
positives
No. of sera
tested
Conditions represented by
sera
No. of sera
tested
No. of
positives
Cross reactivity
(%)
1 2 182 U.S. Negatives 207 3 1
NT NT NT Amebiasis 2 1 50
7 1 14 Ascariasis 8 1 13
0 0 1 Baylisascariasis 1 0 0
50 1 2 Cancer 2 0 0
0 0 2 Cysticercosis 4 0 0
NT NT NT Diroﬁlariasis 1 0 0
50 1 2 Echinococcosis 5 0 0
0 0 2 Eosinophilic myalgia 1 0 0
10 6 63 Filiariasis 63 6 10
50 2 4 Gnathostomiasis NT NT NT
33 2 6 Hookworm (N. americanus) 14 2 14
NT NT NT Hymenolepiaisis 3 1 33
NT NT NT Paragonimiasis 6 0 0
0 0 4 Schistosomiasis 5 0 0
NT NT NT Taeniasis 4 0 0
12 4 33 Toxocariasis 28 1 4
0 0 4 Toxoplasmosis 3 0 0
25 1 4 Trichinellosis 4 1 25
100 2 2 Trichuriasis 4 1 25
NT NT NT Tuberculosis 1 0 0
NT = Not tested
doi:10.1371/journal.pntd.0003694.t002
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Fluorescent Bead Ss- NIE-1 IgG4 Assay
The His tagged Ss-NIE-1 recombinant protein could not be coupled to magnetic beads. Thus,
we proceeded using a GST-tagged Ss-NIE-1 protein and successfully coupled the Ss-NIE-1 pro-
tein to the MagPlex microspheres. The intra- and inter-assay coefficients of variation were de-
termined to be 4.2% and 13.9%, respectively, for average values of 641 MFI and 585. Using a
cutoff value of 8 MFI, the sensitivity and specificity of the IgG4 Luminex assay were 93% and
95% (Table 1), respectively. As with the ELISA described above, the specificity among US nega-
tive controls was much higher (99%) than among donors with defined diseases or parasitic in-
fections (91%) (Table 2). High reactivities (33%) were only observed among sera from the
two amebiasis and three hymenolepiasis donors. The J-index was identical to that of the ELISA
at 0.88.
Post Treatment Analysis
Antibody longevity in subjects infected with strongyloidiasis following treatment with thiaben-
dazole [18] can be seen in Table 3. Peak and median antibody responses decreased over time
using both assay formats, but the antibody levels remained above the cut-off point for most of
the subjects even 18 months post treatment. Using the Kobayashi criteria of cure, which con-
siders a patient to be cured if the ratio of serological results post-treatment compared to pre-
treatment is less than 0.6, 70% of the subjects would be reported as cured 3–6 months following
treatment [27].
Discussion
Strongyloidiasis is an increasingly important health problem in the US among immigrants and
refugees. Patients with occult strongyloidiasis are at risk of disease if they become immunosup-
pressed, and organ donors with unrecognized S. stercoralis infection pose a risk to recipients if
their infected organs are transplanted [2]. Identification of the parasite in stool specimens is in-
sensitive, and, because parasitological examination requires collection of multiple stool speci-
mens over 3 days, serological testing would be preferred if available. We elected to develop
novel immunodiagnostic assays to meet this need. We employed a well described recombinant
protein with proven performance as an immunodiagnostic antigen, the Ss-NIE-1 protein [6–
8]. Based on the potential importance of IgG4 antibody responses in filarial infections, we de-
cided to develop methods that detect S. stercoralis-specific IgG4 antibodies. The Ss-NIE-1 IgG4
Table 3. Change in antibody response following treatment.
At baseline < 3 MONTHS 3–6 MONTHS 7–9 MONTHS 10–18 MONTHS > 18 MONTHS
ELISA† Luminex† ELISA Luminex ELISA Luminex ELISA Luminex ELISA Luminex ELISA Luminex
No. tested 48 25 2 1 26 11 21 12 22 12 9 7
Range 0–255 11–20321 0.5–9.7 480 0–89 3–9483 0.5–77 8–7447 0–33.3 15–6440 0–16.5 20–3324
Mean 28.8 3247 5.1 480 14.4 1663 16.3 1622 7.5 1293.3 3.7 1118
Median 13.8 596 5.1 480 5.9 448 4.6 241 3.5 168 1.8 81
Ratio < 0.6 (%) * 50 0 70 82 68 73 88 83 71 71
Ratio Range 0.3–2.3 0.7–0.7 0.1–1.4 0.2–0.9 0.1–2.2 0.1–0.8 0–3.3 0.1–1.4 0–2.4 0.1–2.3
Note:
† For SS-NIE-1 ELISA, units are expressed in ng/mL and for SS-NIE-1 Luminex, the unit is a ratio of mean ﬂuorescent intensity minus the background of
the test/control.
*Follow-up serologic result divided by the initial result
doi:10.1371/journal.pntd.0003694.t003
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Luminex bead assay achieved a sensitivity and a specificity comparable to those reported for
other strongyloidiasis assays such as the crude antigen ELISA, and 26-kDA ELISA, and Ss-
NIE-1 ELISAs and the Ss-NIE-1 LIPS [6, 7, 9, 10, 12, 18]. Compared to the CDC S. stercoralis
crude antigen ELISA, the Ss-NIE-1 IgG4 ELISA and the Ss-NIE-1 IgG4 Luminex assay achieved
similar sensitivity without compromising specificity. The possible factors contributing to im-
proved specificity could be the use of recombinant antigen, assay optimization, or detection of
IgG4 versus IgG. During Ss-NIE-1 ELISA optimization, we found that non-specific antibody
binding in the normal human sera could be decreased by adding a pre-blocking step with 10
mM nickel chloride in PBS/0.3% Tween/5% milk. The decrease in background noise allows the
assay to have a higher specificity (93%).
ELISA based tests can only be used to detect antibody responses against one antigen of in-
terest at a time. Because the differential diagnosis of S. stercoralis often includes multiple hel-
minths, a submitted serum sample must frequently be tested using several parasite-specific
ELISAs to determine the possible cause(s) of infection. xMAP Luminex technology offers an
assay platform that can simultaneously detect antibodies to multiple diseases/infections, and
multiplex bead-based antibody assays are generally as sensitive as conventional ELISA, have a
wide dynamic range, and are highly reproducible from assay to assay [28]. For these reasons,
we elected to transfer the Ss-NIE-1 assay to the Luminex platform. In our hands, the Ss-NIE-1
IgG4 Luminex bead assay was slightly less sensitive and slightly more specific than the ELISA,
but had comparable overall performance as measured by the J-index.
With the exception of toxocariasis and lymphatic filariasis, our cross-reactivity data must be
interpreted with some caution due to the small numbers of samples available for testing. When
sera from echinococcosis, hookworm, and trichuriasis patients were tested with Ss-NIE-1 by
ELISA, 33% or more of the sera reacted, some quite strongly. A portion of this reactivity likely
resulted from ELISA-specific background as many of these same sera did not react with the Ss-
NIE-1 antigen in our newly developed Luminex bead assay. Bisoffi et al. [9] found no ELISA or
LIPS assay cross-reactions to Ss-NIE-1 among their Echinococcus- or hookworm-infected do-
nors. Although true cross-reactivity between these parasites may exist, polyparasitism cannot
be ruled out in the remaining Luminex-positive subjects. An analysis of Ss-NIE-1 LIPS results
from a hookworm/ Ascaris lumbricoides/ H. nana/ S. stercoralis co-endemic region of Argen-
tina failed to demonstrate an association between infection with other parasites and an anti-
body response to the Ss-NIE-1 antigen [10].
The Ss-NIE-1 ELISA and Luminex had 10% cross-reactivity against the subjects with lym-
phatic filariasis. Again, this problem could be a true cross-reactivity or could also be explained
by polyparasitism with soil-transmitted helminthes in Haiti. Unfortunately, we have no data
about the presence of other parasitic infections in the individuals from whom these serum sam-
ples were obtained [29]. Norsyahida [11] reported that although the use of IgG4 conjugate did
decrease the cross-reactivity to filariasis compared to the total IgG responses, some cross-reac-
tivity was found with the IgG4 based assay. However, the Norsyahida group did not use a recom-
binant antigen [8], and the observed cross-reactivity could be due to the use of crude extract
antigen in their assay. Of note, the group mentioned the importance of testing for filariasis in
subjects with strongyloidiasis. Such testing could most easily be accomplished on a multiplexing
platform such as Luminex that can detect antibodies against filariasis and strongyloidiasis
simultaneously.
Decreases in antibody titers post-treatment were observed (as suggested by Satoh [30]) and
the percentage of patients who met the serologic definition of cure (40% decline in antibody
response compared to pre-treatment) were consistent with the previous reports [18]. The only
significant difference was that the CDC S. stercoralis crude ELISA results showed that 92%of
subjects at>9–18 months had been cured of S. stercoralis infection, but only 71% could be
Ss-NIE-1 and Strongyloidiasis
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considered as cured based on the SS-NIE-1 ELISA and Luminex assay. We have no definitive
explanation for these observed differences, except the fact that the crude ELISA uses a complex
antigen versus a single antigen which was used in our studies.
Overall, excellent assays for detecting S. stercoralis specific antibodies have been developed.
Because these assays use recombinant proteins, negating the need for native parasite materials
these assays can be adopted for use in public health laboratories for refugee screening or in
commercial laboratories for diagnosis of clinical strongyloidiasis and for screening possible
transplant donors with occult disease. As both ELISA and Luminex based assays performed
similarly, studies in low infrastructure, endemic setting could use the ELISA format. Although
polyparasitism is a potential problem, with a strong specificity of 93%, cross-reactivity should
not be an issue. For a country-wide study to determine the prevalence of strongyloidiasis, a
multiplexing capability of Luminex will be more cost efficient.
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